HRMY — Harmony Biosciences Holdings, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802665 ·
Last close
$41.26
Market Cap
$2.40B
52W High
$43.49
52W Low
$25.52
ADV30
918,587
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 261,280,000 | 198,082,000 | 89,316,000 | 75,431,000 | 1,373,084,000 | 549,769,000 | 373,841,000 |
| Mar 2026 | 215,387,000 | 170,875,000 | 37,291,000 | 32,488,000 | 1,271,824,000 | 589,398,000 | 361,475,000 |
| Dec 2025 | 243,776,000 | 175,231,000 | 38,557,000 | 22,486,000 | 1,271,631,000 | 752,502,000 | 401,413,000 |
| Sep 2025 | 239,455,000 | 179,805,000 | 65,487,000 | 50,865,000 | 1,208,218,000 | 646,999,000 | 373,095,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$355,077,000
Investing CF
$-337,571,000
Financing CF
$-13,787,000
CapEx
$-310,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$3.08
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$268,822,000
Inventory
$6,360,000
Receivables
$110,995,000
ST Investments
$118,022,000
EBIT TTM
$254,673,000
Pretax Income TTM
$241,202,000
Interest Exp TTM
$13,471,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$959,897,984
EBITDA
$255,987,008
Free Cash Flow
$182,835,504
Enterprise Value
$1,910,375,040
Total Cash
$667,790,976
Total Debt
$160,191,008
Shares Out
58,236,393
Trailing EPS
$3.09
Book Value
$17.19
ROE
20.5%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 868,453,000 | 208,469,000 | 158,687,000 | 1,271,631,000 | 401,413,000 | 870,218,000 | 348,199,000 |
| Dec 2024 | 714,734,000 | 190,826,000 | 145,493,000 | 999,200,000 | 340,045,000 | 659,155,000 | 219,821,000 |
| Dec 2023 | 582,022,000 | 192,030,000 | 128,853,000 | 811,448,000 | 344,456,000 | 466,992,000 | 219,387,000 |
| Dec 2022 | 437,855,000 | 120,186,000 | 181,468,000 | 673,870,000 | 271,032,000 | 402,838,000 | 144,466,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$6.69
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $41.26 · call volume: 2,289 · put volume: 16
Expected Move to 2027-04-16:
±$19.65
(47.62%) —
implied range
$21.61 –
$60.91
· ATM straddle on $42.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | $2.39B | $23.01 | — |
| HCM | HUTCHMED (China) Ltd | $2.42B | $13.94 | — |
| IMNM | Immunome Inc. | $2.43B | $21.41 | — |
| VERA | Vera Therapeutics, Inc. | $2.34B | $32.54 | — |
| SLS | SELLAS Life Sciences Group, Inc. | $2.34B | $11.61 | — |
News headlines (Yahoo Finance, 1h cache)
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
2026-09-03 15:30 · Yahoo
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
2026-09-03 12:05 · Yahoo
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
2026-08-14 14:04 · Yahoo
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript
2026-08-11 17:29 · Yahoo
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
2026-08-26 13:41 · Yahoo
BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
2026-08-11 16:45 · Yahoo
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
2026-08-10 17:05 · Yahoo
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
2026-08-10 15:27 · Yahoo
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline Progress - What's Changed
2026-08-07 23:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.